[3-[4-(Imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: [3-[4-(Imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamic acid
• 英文别名: [3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamic acid
• 化学式: C₁₉H₂₁N₃O₄S₂
• 分子量: 419.5
• InChiKey: YTVRYRCOOGKIBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II<br/>[FR] NOUVEAUX COMPOSÉS UTILES DANS LE TRAITEMENT ET/OU LA PRÉVENTION D'UNE MALADIE, D'UN TROUBLE OU D'UN ÉTAT DE SANTÉ ASSOCIÉ À L'ANGIOTENSINE II
  申请人：VICORE PHARMA AB

  公开号：WO2021186185A1

  公开（公告）日：2021-09-23

  The present disclosure relates to compounds of Formula (I) and to their utility in the treatment in a disease, disorder and/or condition associated with the peptide angiotensin II.

  本公开涉及I式化合物及其在治疗与肽血管紧张素II相关的疾病、紊乱和/或病况中的效用。
• MODULATION OF ANGIOTENSIN II RECEPTORS FOR THE PREVENTION AND TREATMENT OF MALARIA CEREBRAL
  申请人：Rodriguez Fernandez Ana Maria

  公开号：US20150119329A1

  公开（公告）日：2015-04-30

  The present invention is directed to a composition for the treatment or prevention of cerebral malaria that comprises an angiotensin receptor type-2 agonist and an antimalaria drug. The present invention is further directed to methods for treating and preventing cerebral malaria that involve administering an angiotensin receptor type-2 agonist and/or an angiotensin receptor type-1 antagonist.
• [EN] MODULATION OF ANGIOTENSIN II PECEPTORS FOR THE PREVENTION AND TREATMENT OF CEREBRAL MALARIA<br/>[FR] MODULATION DES RÉCEPTEURS DE L'ANGIOTENSINE II POUR LA PRÉVENTION ET LE TRAITEMENT DE L'ACCÈS PERNICIEUX À FORME CÉRÉBRALE
  申请人：UNIV NEW YORK

  公开号：WO2013158628A1

  公开（公告）日：2013-10-24

  The present invention is directed to a composition for the treatment or prevention of cerebral malaria that comprises an angiotensin receptor type-2 agonist and an antimalaria drug. The present invention is further directed to methods for treating and preventing cerebral malaria that involve administering an angiotensin receptor type-2 agonist and/or an angiotensin receptor type- 1 antagonist.